156 related articles for article (PubMed ID: 25387724)
1. Immunological effects and therapeutic role of C5a in cancer.
Darling VR; Hauke RJ; Tarantolo S; Agrawal DK
Expert Rev Clin Immunol; 2015 Feb; 11(2):255-63. PubMed ID: 25387724
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the antitumor immune response by complement.
Markiewski MM; DeAngelis RA; Benencia F; Ricklin-Lichtsteiner SK; Koutoulaki A; Gerard C; Coukos G; Lambris JD
Nat Immunol; 2008 Nov; 9(11):1225-35. PubMed ID: 18820683
[TBL] [Abstract][Full Text] [Related]
3. Role of C5a in inflammatory responses.
Guo RF; Ward PA
Annu Rev Immunol; 2005; 23():821-52. PubMed ID: 15771587
[TBL] [Abstract][Full Text] [Related]
4. Cancer and complement.
Ostrand-Rosenberg S
Nat Biotechnol; 2008 Dec; 26(12):1348-9. PubMed ID: 19060872
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells in malignant melanoma.
Umansky V; Sevko A; Gebhardt C; Utikal J
J Dtsch Dermatol Ges; 2014 Nov; 12(11):1021-7. PubMed ID: 25263083
[TBL] [Abstract][Full Text] [Related]
6. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness.
Nitta H; Murakami Y; Wada Y; Eto M; Baba H; Imamura T
Oncol Rep; 2014 Oct; 32(4):1715-9. PubMed ID: 25050844
[TBL] [Abstract][Full Text] [Related]
7. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.
Jiang H; Gebhardt C; Umansky L; Beckhove P; Schulze TJ; Utikal J; Umansky V
Int J Cancer; 2015 May; 136(10):2352-60. PubMed ID: 25353097
[TBL] [Abstract][Full Text] [Related]
8. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
9. Complement component 5a (C5a).
Manthey HD; Woodruff TM; Taylor SM; Monk PN
Int J Biochem Cell Biol; 2009 Nov; 41(11):2114-7. PubMed ID: 19464229
[TBL] [Abstract][Full Text] [Related]
10. Cancer exploiting complement: a clue or an exception?
Loveland BE; Cebon J
Nat Immunol; 2008 Nov; 9(11):1205-6. PubMed ID: 18936777
[No Abstract] [Full Text] [Related]
11. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses.
Rudilla F; Fayolle C; Casares N; Durantez M; Arribillaga L; Lozano T; Villanueva L; Pio R; Sarobe P; Leclerc C; Prieto J; Lasarte JJ
Vaccine; 2012 Apr; 30(18):2848-58. PubMed ID: 22387222
[TBL] [Abstract][Full Text] [Related]
12. C5a contributes to intraocular inflammation by affecting retinal pigment epithelial cells and immune cells.
Hu M; Liu B; Jawad S; Ling D; Casady M; Wei L; Nussenblatt RB
Br J Ophthalmol; 2011 Dec; 95(12):1738-44. PubMed ID: 21873312
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
14. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
[TBL] [Abstract][Full Text] [Related]
15. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche.
Vadrevu SK; Chintala NK; Sharma SK; Sharma P; Cleveland C; Riediger L; Manne S; Fairlie DP; Gorczyca W; Almanza O; Karbowniczek M; Markiewski MM
Cancer Res; 2014 Jul; 74(13):3454-65. PubMed ID: 24786787
[TBL] [Abstract][Full Text] [Related]
16. Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment.
Kosni NN; Ganti N; Noor MH; Razak IS; Ajat MM; Omar AR
J Cancer Res Ther; 2016; 12(2):590-6. PubMed ID: 27461615
[TBL] [Abstract][Full Text] [Related]
17. A novel interpretation of immune redundancy and duality in reperfusion injury with important implications for intervention in ischaemic disease.
Thrane AS; Skehan JD; Thrane PS
Med Hypotheses; 2007; 68(6):1363-70. PubMed ID: 17169498
[TBL] [Abstract][Full Text] [Related]
18. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.
Mao Y; Poschke I; Wennerberg E; Pico de Coaña Y; Egyhazi Brage S; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Cancer Res; 2013 Jul; 73(13):3877-87. PubMed ID: 23633486
[TBL] [Abstract][Full Text] [Related]
19. Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.
Imamura T; Yamamoto-Ibusuki M; Sueta A; Kubo T; Irie A; Kikuchi K; Kariu T; Iwase H
Breast Cancer; 2016 Nov; 23(6):876-885. PubMed ID: 26494574
[TBL] [Abstract][Full Text] [Related]
20. LPS induces pulp progenitor cell recruitment via complement activation.
Chmilewsky F; Jeanneau C; Laurent P; About I
J Dent Res; 2015 Jan; 94(1):166-74. PubMed ID: 25359783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
